作者
Laszlo G Radvanyi, Chantale Bernatchez, Minying Zhang, Patricia S Fox, Priscilla Miller, Jessica Chacon, Richard Wu, Gregory Lizee, Sandy Mahoney, Gladys Alvarado, Michelle Glass, Valen E Johnson, John D McMannis, Elizabeth Shpall, Victor Prieto, Nicholas Papadopoulos, Kevin Kim, Jade Homsi, Agop Bedikian, Wen-Jen Hwu, Sapna Patel, Merrick I Ross, Jeffrey E Lee, Jeffrey E Gershenwald, Anthony Lucci, Richard Royal, Janice N Cormier, Michael A Davies, Rahmatu Mansaray, Orenthial J Fulbright, Christopher Toth, Renjith Ramachandran, Seth Wardell, Audrey Gonzalez, Patrick Hwu
发表日期
2012/12/15
期刊
Clinical Cancer Research
卷号
18
期号
24
页码范围
6758-6770
出版商
American Association for Cancer Research
简介
Purpose: Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) is a promising treatment for metastatic melanoma unresponsive to conventional therapies. We report here on the results of an ongoing phase II clinical trial testing the efficacy of ACT using TIL in patients with metastatic melanoma and the association of specific patient clinical characteristics and the phenotypic attributes of the infused TIL with clinical response.
Experimental Design: Altogether, 31 transiently lymphodepleted patients were treated with their expanded TIL, followed by two cycles of high-dose interleukin (IL)-2 therapy. The effects of patient clinical features and the phenotypes of the T cells infused on the clinical response were determined.
Results: Overall, 15 of 31 (48.4%) patients had an objective clinical response using immune-related response criteria (irRC) with 2 patients (6.5 …
学术搜索中的文章
LG Radvanyi, C Bernatchez, M Zhang, PS Fox, P Miller… - Clinical Cancer Research, 2012